Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging immunotherapies in multiple myeloma
Urvi A. Shah, Sham Mailankody
BMJ (2020), pp. m3176-m3176
Open Access | Times Cited: 113

Showing 1-25 of 113 citing articles:

NF-κB in biology and targeted therapy: new insights and translational implications
Qing Guo, Yizi Jin, Xinyu Chen, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 394
GPRC5D-Targeted CAR T Cells for Myeloma.
Sham Mailankody, Sean M. Devlin, Jonathan Landa, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 13, pp. 1196-1206
Open Access | Times Cited: 260
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
Oliver Van Oekelen, Adolfo Aleman, Bhaskar Upadhyaya, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2099-2103
Open Access | Times Cited: 166
Mechanisms of Therapeutic Antitumor Monoclonal Antibodies
Li-Chung Tsao, Jeremy Force, Zachary C. Hartman
Cancer Research (2021) Vol. 81, Iss. 18, pp. 4641-4651
Open Access | Times Cited: 142
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
Muthulekha Swamydas, Elena V. Murphy, James J. Ignatz-Hoover, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 81
Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies
Cheng Wang, Shu Guang Dai, Xingtao Zhao, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 163, pp. 114882-114882
Open Access | Times Cited: 50
Targeted immunotherapy: harnessing the immune system to battle multiple myeloma
Limei Xu, Caining Wen, Jiang Xia, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 12
BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice
Xiang Zhou, Leo Rasche, K. Martin Kortüm, et al.
Haematologica (2022) Vol. 108, Iss. 4, pp. 958-968
Open Access | Times Cited: 32
The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies
Claire Comerford, Siobhán Glavey, John Quinn, et al.
Journal of Thrombosis and Haemostasis (2022) Vol. 20, Iss. 8, pp. 1766-1777
Open Access | Times Cited: 28
Andrographolide induced ferroptosis in multiple myeloma cells by regulating the P38/Nrf2/HO-1 pathway
Wenxia Li, Hangjie Fu, Liuyuan Fang, et al.
Archives of Biochemistry and Biophysics (2023) Vol. 742, pp. 109622-109622
Closed Access | Times Cited: 18
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
Francesco Maura, Eileen M. Boyle, David G. Coffey, et al.
Nature Cancer (2023) Vol. 4, Iss. 12, pp. 1660-1674
Closed Access | Times Cited: 17
Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma
Qizhong Lu, Donghui Yang, Hexian Li, et al.
Cancer Letters (2024) Vol. 585, pp. 216660-216660
Closed Access | Times Cited: 7
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
Paola Neri, Noémie Leblay, Holly Lee, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 8, pp. 590-609
Closed Access | Times Cited: 7
Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma
S. Yuan, Ying Chen, Huasheng Liu
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access | Times Cited: 6
Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β
Donald C. Vinh, Laurent Abel, Paul Bastard, et al.
Journal of Clinical Immunology (2021) Vol. 41, Iss. 7, pp. 1425-1442
Open Access | Times Cited: 40
IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma
Jennifer Sun, S. Corradini, Feda Azab, et al.
Leukemia (2024)
Open Access | Times Cited: 5
Efficacy and safety of a modified DVD regimen followed by lenalidomide for the treatment of Newly Diagnosed Multiple Myeloma
Zhichao Li, Wenhao Zhang, Fang Huang, et al.
Clinics (2025) Vol. 80, pp. 100575-100575
Open Access
Progress of immune senescence in multiple myeloma treatment resistance
Yanan Jia, Lixiang Yan, Chenyang Fan, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma
Bachisio Ziccheddu, Claudia Giannotta, Mattia D’Agostino, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Multifunctional tumor vaccines carrying thalidomide regulate T cell exhaustion and ferroptosis for immunotherapy strategies
Aijin Huang, Ting Li, Ying Zhou, et al.
View (2025)
Open Access
Novel Experimental Drugs for Treatment of Multiple Myeloma
Massimo Offidani, Laura Corvatta, Sonia Morè, et al.
Journal of Experimental Pharmacology (2021) Vol. Volume 13, pp. 245-264
Open Access | Times Cited: 24
Splicing factor arginine/serine‐rich 8 promotes multiple myeloma malignancy and bone lesion through alternative splicing of CACYBP and exosome‐based cellular communication
Yuanjiao Zhang, Xichao Yu, Rongze Sun, et al.
Clinical and Translational Medicine (2022) Vol. 12, Iss. 2
Open Access | Times Cited: 18
Exosomal miR-483-5p in Bone Marrow Mesenchymal Stem Cells Promotes Malignant Progression of Multiple Myeloma by Targeting TIMP2
Jianmei Gu, Maoye Wang, Xinfeng Wang, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 18
Immunotherapy approaches for hematological cancers
Olivia L. Lanier, Edgar Pérez‐Herrero, Abielle P. D.’ Andrea, et al.
iScience (2022) Vol. 25, Iss. 11, pp. 105326-105326
Open Access | Times Cited: 18
CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours
Hiu Kwan Carolyn Tang, Bo Wang, Hui Xian Tan, et al.
Cells (2023) Vol. 12, Iss. 12, pp. 1586-1586
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top